Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

A. J. van der Wekken*, R. Pelgrim, N. 't Hart, N. Werner, M. F. Mastik, L. Hendriks, E. H. F. M. van der Heijden, M. Looijen-Salamon, A. J. de langen, J. Staal-van den Brekel, S. Riemersma, B. E. van den Borne, E. J. M. Speel, A-M. C. Dingemans, T. J. N. Hiltermann, A. van den Berg, W. Timens, E. Schuuring, H. J. M. Groen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4251-4258
Number of pages8
JournalClinical Cancer Research
Volume23
Issue number15
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • IN-SITU HYBRIDIZATION
  • CRIZOTINIB THERAPY
  • GENE REARRANGEMENT
  • COPY NUMBER
  • IMMUNOHISTOCHEMISTRY
  • ADENOCARCINOMA
  • IDENTIFICATION
  • CARCINOMAS
  • ONCOLOGY
  • FUSION

Cite this

van der Wekken, A. J. ; Pelgrim, R. ; 't Hart, N. ; Werner, N. ; Mastik, M. F. ; Hendriks, L. ; van der Heijden, E. H. F. M. ; Looijen-Salamon, M. ; de langen, A. J. ; Staal-van den Brekel, J. ; Riemersma, S. ; van den Borne, B. E. ; Speel, E. J. M. ; Dingemans, A-M. C. ; Hiltermann, T. J. N. ; van den Berg, A. ; Timens, W. ; Schuuring, E. ; Groen, H. J. M. / Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 15. pp. 4251-4258.
@article{620c8dfc86364006b68cdf0b49b5e956,
title = "Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer",
keywords = "IN-SITU HYBRIDIZATION, CRIZOTINIB THERAPY, GENE REARRANGEMENT, COPY NUMBER, IMMUNOHISTOCHEMISTRY, ADENOCARCINOMA, IDENTIFICATION, CARCINOMAS, ONCOLOGY, FUSION",
author = "{van der Wekken}, {A. J.} and R. Pelgrim and {'t Hart}, N. and N. Werner and Mastik, {M. F.} and L. Hendriks and {van der Heijden}, {E. H. F. M.} and M. Looijen-Salamon and {de langen}, {A. J.} and {Staal-van den Brekel}, J. and S. Riemersma and {van den Borne}, {B. E.} and Speel, {E. J. M.} and Dingemans, {A-M. C.} and Hiltermann, {T. J. N.} and {van den Berg}, A. and W. Timens and E. Schuuring and Groen, {H. J. M.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-16-1631",
language = "English",
volume = "23",
pages = "4251--4258",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

van der Wekken, AJ, Pelgrim, R, 't Hart, N, Werner, N, Mastik, MF, Hendriks, L, van der Heijden, EHFM, Looijen-Salamon, M, de langen, AJ, Staal-van den Brekel, J, Riemersma, S, van den Borne, BE, Speel, EJM, Dingemans, A-MC, Hiltermann, TJN, van den Berg, A, Timens, W, Schuuring, E & Groen, HJM 2017, 'Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer', Clinical Cancer Research, vol. 23, no. 15, pp. 4251-4258. https://doi.org/10.1158/1078-0432.CCR-16-1631

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. / van der Wekken, A. J.; Pelgrim, R.; 't Hart, N.; Werner, N.; Mastik, M. F.; Hendriks, L.; van der Heijden, E. H. F. M.; Looijen-Salamon, M.; de langen, A. J.; Staal-van den Brekel, J.; Riemersma, S.; van den Borne, B. E.; Speel, E. J. M.; Dingemans, A-M. C.; Hiltermann, T. J. N.; van den Berg, A.; Timens, W.; Schuuring, E.; Groen, H. J. M.

In: Clinical Cancer Research, Vol. 23, No. 15, 01.08.2017, p. 4251-4258.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

AU - van der Wekken, A. J.

AU - Pelgrim, R.

AU - 't Hart, N.

AU - Werner, N.

AU - Mastik, M. F.

AU - Hendriks, L.

AU - van der Heijden, E. H. F. M.

AU - Looijen-Salamon, M.

AU - de langen, A. J.

AU - Staal-van den Brekel, J.

AU - Riemersma, S.

AU - van den Borne, B. E.

AU - Speel, E. J. M.

AU - Dingemans, A-M. C.

AU - Hiltermann, T. J. N.

AU - van den Berg, A.

AU - Timens, W.

AU - Schuuring, E.

AU - Groen, H. J. M.

PY - 2017/8/1

Y1 - 2017/8/1

KW - IN-SITU HYBRIDIZATION

KW - CRIZOTINIB THERAPY

KW - GENE REARRANGEMENT

KW - COPY NUMBER

KW - IMMUNOHISTOCHEMISTRY

KW - ADENOCARCINOMA

KW - IDENTIFICATION

KW - CARCINOMAS

KW - ONCOLOGY

KW - FUSION

U2 - 10.1158/1078-0432.CCR-16-1631

DO - 10.1158/1078-0432.CCR-16-1631

M3 - Article

VL - 23

SP - 4251

EP - 4258

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -